Chemistry:Relfovetmab

From HandWiki

Relfovetmab, sold under the brand name Portela, is a felinized monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats.[1] Relfovetmab targets nerve growth factor.[1] Nerve growth factor binds to TrkA receptors located on immune cells to elicit the release of additional proinflammatory mediators, including nerve growth factor itself.[2] These inflammatory mediators lead to further peripheral sensitization involved in pain perception.[2] The inhibition of nerve growth factor was demonstrated to provide relief from pain associated with osteoarthritis.[2]

Relfovetmab was authorized for veterinary use in the European Union in October 2025,[3] and in Canada in December 2025.[4]

Medical uses

Relfovetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.[5]

Society and culture

In September 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Portela, solution for injection, intended for cats.[2] The applicant for this veterinary medicinal product is Zoetis Belgium.[2] Relfovetmab was authorized for veterinary use in the European Union in October 2025.[3]

Relfovetmab was authorized for veterinary use in Canada in December 2025.[4]

Names

Relfovetmab is the international nonproprietary name.[6]

Relfovetmab is sold under the brand name Portela.[3][4]

References

  1. ↑ 1.0 1.1 Cite error: Invalid <ref> tag; no text was provided for refs named EMA Portela
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "Portela EPAR". 12 September 2025. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/portela.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ↑ 3.0 3.1 3.2 "Zoetis Receives European Commission Marketing Authorization for Portela (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats" (Press release). Zoetis. 29 October 2025. Retrieved 22 December 2025 – via Business Wire.
  4. ↑ 4.0 4.1 4.2 "Zoetis Receives Health Canada Approval for Portela (relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats" (Press release). Zoetis. 5 December 2025. Retrieved 22 December 2025 – via Business Wire.
  5. ↑ "Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 9-10 September 2025". 12 September 2025. https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-products-cvmp-9-10-september-2025. 
  6. ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information 33 (3). 2019. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Relfovetmab&oldid=4243004"